In a welcome move, GSK ADR saw its Relative Strength Rating rise from 66 to 74 on Monday.
Can You Really Time The Stock Market?
This unique rating identifies market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the trailing 52 weeks compares to the rest of the market.
Decades of market research reveals that the market's biggest winners tend to have an RS Rating north of 80 in the early stages of their moves. See if GSK ADR can continue to rebound and hit that benchmark.
GSK ADR is still inside a buying range after moving past a 40.38 entry in a cup with handle. Once a stock moves 5% or higher beyond the initial entry, it's considered extended and out of buy range.
The company saw both earnings and sales growth rise last quarter. Earnings-per-share increased from -22% to 6%. Revenue rose from -1% to 4%.
GSK ADR holds the No. 1 rank among its peers in the Medical-Diversified industry group. Abbott Laboratories and AstraZeneca ADR are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
